Cytek Biosciences, Inc.
CTKB
$3.77
-$0.05-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.64M | 940.00K | -10.43M | -6.17M | 5.50M |
| Total Depreciation and Amortization | 2.74M | 2.81M | 2.48M | 2.46M | 2.43M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.89M | 6.21M | 6.05M | 5.82M | 5.42M |
| Change in Net Operating Assets | -5.50M | 3.26M | 8.11M | 1.85M | -3.84M |
| Cash from Operations | 2.00M | 13.22M | 6.20M | 3.96M | 9.51M |
| Capital Expenditure | -894.00K | -1.01M | -1.05M | -567.00K | -1.50M |
| Sale of Property, Plant, and Equipment | 191.00K | 21.00K | 76.00K | -- | -- |
| Cash Acquisitions | -471.00K | -- | -- | -- | -236.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.26M | -14.82M | 3.00M | -5.19M | 30.80M |
| Cash from Investing | -63.43M | -15.81M | 2.02M | -5.75M | 29.07M |
| Total Debt Issued | 2.79M | 5.00K | -3.00K | 1.39M | -- |
| Total Debt Repaid | -139.00K | -140.00K | -139.00K | -139.00K | -140.00K |
| Issuance of Common Stock | 835.00K | 147.00K | 1.23M | 506.00K | 1.23M |
| Repurchase of Common Stock | -7.12M | -12.10M | -2.80M | -148.00K | -34.84M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3.64M | -12.08M | -1.71M | 1.61M | -33.75M |
| Foreign Exchange rate Adjustments | 1.52M | -943.00K | 2.26M | 1.70M | -823.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.56M | -15.62M | 8.78M | 1.51M | 4.00M |